|
|||||
|
|
| Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective ‘proof of concept’ phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA) | |
| 摘 要： | |
| 本文献已被 ScienceDirect 等数据库收录！ | |